- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dual Mechanism Dry Eye Treatment Shows Promise for Symptoms and Compliance
Richard Adler, MD, FACS, provides perspective on AAO 2023 data suggesting dual mechanism treatment targeting aqueous deficiency and meibomian gland dysfunction may improve dry eye symptoms more significantly and faster than singular therapies, benefiting patient compliance and disease management.
EP: 1.Navigating Unmet Needs in Dry Eye Disease Therapies
EP: 2.Key Takeaways from Phase 4 Switch Trial Presented at AAO
EP: 3.Real World Benefit Related to Improving Corneal Staining
EP: 4.Overview of Phase 3 Perfluorohexyloctane Studies at AAO 2023
EP: 5.Updates from the SAHARA Trial at AAO 2023
EP: 6.Dual Mechanism Dry Eye Treatment Shows Promise for Symptoms and Compliance
This is a video synopsis/summary of a Post Conference Perspectives featuring Richard Adler, MD.
Adler discusses additional perspective on results from the SAHARA trial comparing the Aqueous Retention and Meibomian Gland Outflow Restoration (ARMOR) procedure to Restasis (cyclosporine ophthalmic emulsion 0.05%) for dry eye disease. While ARMOR showed superior improvement in tear break-up time, a sign of evaporative dry eye, it did not demonstrate significantly better relief of symptoms compared with Restasis.
However, Adler notes this highlights the complex, multifactorial nature of dry eye requiring multiple treatment modalities to comprehensively address signs and symptoms. As Restasis targets the aqueous deficiency aspect whereas ARMOR specifically treats the evaporative component, using them together could have complementary effects. Though the study premises were not perfectly matched, the results still validate using ARMOR to improve evaporative signs.
Overall, the plethora of new research and innovations presented for dry eye reflects the rapidly expanding therapeutic landscape and opportunities to better treat this condition. Even existing strategies are being improved upon. There remains exciting potential for advancing dry eye management.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Integrated Care for Chronic Conditions: A Randomized Care Management Trial
December 3rd 2025The authors sought to understand the differential impact of payer-led community-based care management approaches on stakeholder-oriented outcomes for publicly insured adults with multiple chronic conditions.
Read More
Managed Care Reflections: A Q&A With A. Mark Fendrick, MD, and Michael E. Chernew, PhD
December 2nd 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The December issue features a conversation with AJMC Co–Editors in Chief A. Mark Fendrick, MD, director of the Center for Value-Based Insurance Design and a professor at the University of Michigan in Ann Arbor; and Michael E. Chernew, PhD, the Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation Lab at Harvard Medical School in Boston, Massachusetts.
Read More
